Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
GILEAD SCIENCES, INC. (GILD) reported that Chairman & CEO Daniel Patrick O'Day exercised restricted stock units into common stock on September 10, 2026. The transaction involved 8,780 restricted stock units converting into 8,780 shares of common stock, with 4,230 shares delivered or withheld for payment of exercise price or tax liability. Following the derivative transaction, 83,300 restricted stock units remained outstanding, subject to a four-year vesting schedule.
GILEAD SCIENCES, INC. (GILD) reported that Chairman and CEO Daniel Patrick O'Day sold a total of 15,000 shares of common stock on September 1, 2026, in three open-market transactions made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. Sale prices across the trades ranged from $146.94 to $149.94 per share.
GILEAD SCIENCES, INC. (GILD) director Anthony Welters reported an exercise-and-sell transaction on August 26, 2026. He exercised non-qualified stock options covering 18,000 shares of common stock at exercise prices of $60.67 and $61.35 per share, acquiring 18,000 shares. He then sold 18,000 shares of GILD common stock in multiple open-market trades at prices ranging from $147.57 to $149.58 per share, pursuant to a Rule 10b5-1 trading plan adopted on May 27, 2026.
GILEAD SCIENCES, INC. (GILD) received a Rule 144 notice that director Anthony Welters plans to sell 18,000 shares of Gilead common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or after August 26, 2026, following an exercise of stock options for cash.
GILEAD SCIENCES, INC. (GILD) director Jeffrey Bluestone reported option exercises and related share sales. On August 20, 2026 he exercised non-qualified stock options for a total of 5,000 shares of common stock at exercise prices of $67.45 and $61.35 per share, from fully vested grants dating to 2021 and 2022. He then sold the 5,000 resulting common shares in multiple trades at prices between $143.31 and $146.36 per share pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.
GILEAD SCIENCES, INC. (GILD) has a notice of proposed sale of securities filed on behalf of director Jeffrey Bluestone under Rule 144. The notice covers the potential sale of 5,000 shares of Gilead common stock, expected on or about 08/20/2026, following an exercise of stock options for cash. The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate value of $738,000.00, and are listed for trading on NASDAQ.
GILEAD SCIENCES, INC. (GILD) reported that its Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on 2026-08-17 at $138.36 per share in an open-market or private transaction. After this sale, he directly holds 165,646 shares. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
GILEAD SCIENCES, INC. (GILD) reported insider equity transactions by Chief Commercial and Corporate Affairs Officer Johanna Mercier. On August 17, 2026, she exercised options for 25,000 shares of common stock (23,110 at a $66.64 exercise price and 1,890 at $72.34). She then sold 28,000 shares of common stock in open-market transactions at prices ranging from $136.74 to $138.36 per share. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on February 20, 2025.
Gilead Sciences insider Johanna Mercier filed a notice to potentially sell up to 28,000 shares of common stock through Morgan Stanley Smith Barney LLC’s Executive Financial Services program. The planned sales are associated with a stock option exercise for 25,000 shares dated 08/17/2026 and 3,000 performance shares dated 02/04/2025.
The filing lists an aggregate market value of approximately $3,853,907.85 for the securities covered and notes prior sales of 3,000 shares on 07/15/2026 for $389,757.60 and 3,000 shares on 06/15/2026 for $371,762.10.
Gilead Sciences insider Andrew Dickinson filed a notice to sell 3,000 shares of common stock of GILD through Morgan Stanley Smith Barney LLC, with an aggregate market value of $415,080.00, expected on August 17, 2026. The shares were acquired as Performance Shares on January 31, 2024. Dickinson previously sold 3,000 shares on June 15, 2026 for $376,200.00 and 3,000 shares on July 15, 2026 for $389,776.80.